INTERNATIONAL CANCER

Molecular profiling connection services/clinical trials matching services: 1) advising patients on the importance of next-generation sequencing and educating them about the array of molecular profiling technologies that can either be accessed by patients and/or researchers--dna, rna, and thus multi-omics: genomics, proteomics, transcriptomics, metabolomics, methylation, immune cell studies, and so forth; 2) reviewing molecular profiling reports with patients and their care partners; 3) convening ad hoc molecular tumor boards where needed, with the input of members of ican's biomarkers council, physicians council, and drug development council; 4) educating patients about molecular tumor boards (e.g. Target cancer's track study, asco tapur study; roche navify); and, 5) connecting patients to principal investigators and study teams on a pan-tumor/pan- heme/pan-rare cancer basis if an appropriate clinical trial is a molecular match. Ican and its support groups are also engaged in the areas of decentralizing trials; "just-in-time" trials; and expediting the transfer of patients from one clinical trials site (mid-regimen) to another more convenient site (u.s. To u.s. Or eu to u.s.). Ican, the exon 20 group, and the met crusaders specialize in clinical trial accrual and retention issues as well as clinical trials site selection issues. The biomarker collaborative 1) connects patients to both the appropriate specific biomarker support group and the relevant general organizations that cover the patient's specific cancer type; and 2) educates patients about their driver mutation, amplification or fusion (if identified by the relevant laboratory's report) as well as their gene co-alterations. Ican and its support organizations each stress the importance of multi-stakeholder collaborations with research advocates, patient advocates, community advocates, clinicians, and scientists.